Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Completed
Pfizer
Phase 2
2009-03-11
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in
patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or
pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15
years) or have known EGFR activating mutation; or patients with HER 2 amplification or
mutation.
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Completed
Pfizer
Phase 3
2011-06-16
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the
efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients
with advanced non-small cell lung cancer, previously treated with at least one prior regimen.
Analyses of primary objective (Progression Free Survival) will be done in two co-primary
populations as defined in the protocol.
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
Completed
Pfizer
Phase 2
2011-12-26
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced
NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To
assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence
of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1
mutation, HER-2 mutation or HER-2 amplification).
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Completed
Pfizer
Phase 2
2012-02-01
This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety
of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene
amplification and/or EGFRvIII mutation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
